BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan Y, Ding K, Su J, Trinh X, Peng Z, Gong Y, Chen L, Cui Q, Lei N, Chen X, Yu R. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: A systematic review and meta-analysis. PLoS One. 2012;7:e32789. [PMID: 22479339 DOI: 10.1371/journal.pone.0032789] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Xu Z, Wu G, Li F, Bai J, Xing W, Zhang D, Zeng C. Positive selection signals of hepatitis B virus and their association with disease stages and viral genotypes. Infection, Genetics and Evolution 2013;19:176-87. [DOI: 10.1016/j.meegid.2013.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
2 Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
4 Kasırga E. Lamivudine resistance in children with chronic hepatitis B. World J Hepatol 2015; 7(6): 896-902 [PMID: 25937866 DOI: 10.4254/wjh.v7.i6.896] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z. Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants. Virol J 2013;10:292. [PMID: 24053482 DOI: 10.1186/1743-422X-10-292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
6 Yang J, Chen G, Chen X, Zhang H, Jiang D, Yang G. Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J. 2015;12:97. [PMID: 26104153 DOI: 10.1186/s12985-015-0323-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Tana MM, Ghany MG. Hepatitis B virus treatment: Management of antiviral drug resistance. Clin Liver Dis (Hoboken) 2013;2:24-8. [PMID: 30992816 DOI: 10.1002/cld.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
9 Mojsiejczuk LN, Torres C, Sevic I, Badano I, Malan R, Flichman DM, Liotta DJ, Campos RH. Molecular epidemiology of hepatitis B virus in Misiones, Argentina. Infect Genet Evol 2016;44:34-42. [PMID: 27321439 DOI: 10.1016/j.meegid.2016.06.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
10 Tan YW, Ye Y, Ge GH, Zhao W, Gan JH, Zhao Y, Niu ZL, Zhang DJ, Chen L, Yu XJ, Yang LJ. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B. World J Gastroenterol 2015; 21(7): 2089-2095 [PMID: 25717242 DOI: 10.3748/wjg.v21.i7.2089] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hamidi-Fard M, Makvandi M, Samarbaf-Zadeh A, Hajiani E, Shayesteh A, Masjedizadeh A. Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran). Indian J Med Microbiol. 2013;31:360-365. [PMID: 24064642 DOI: 10.4103/0255-0857.118882] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One 2016;11:e0164210. [PMID: 27711135 DOI: 10.1371/journal.pone.0164210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M, Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy in HBV-infected patients with low baseline viremia and early virological response: A multicenter study. J Dig Dis 2015;16:286-92. [PMID: 25708813 DOI: 10.1111/1751-2980.12237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Yeh ML, Huang CI, Hsieh MY, Huang CF, Hsieh MH, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. Kaohsiung J Med Sci 2016;32:559-66. [PMID: 27847098 DOI: 10.1016/j.kjms.2016.08.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Fernández-Galindo DA, Sánchez-Ávila F, Bobadilla-Morales L, Gómez-Quiróz P, Bueno-Topete M, Armendáriz-Borunda J, Sánchez-Orozco LV. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H. J Med Virol 2015;87:985-92. [PMID: 25732900 DOI: 10.1002/jmv.24098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
16 Yang J, Chen X, Zhang H, Chen G. HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma. J Med Virol. 2014;86:913-917. [PMID: 24615989 DOI: 10.1002/jmv.23895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
18 Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, An Y, Wang L. Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis: Hepatitis B virus natural mutation rate. J Gastroenterol Hepatol 2015;30:252-61. [DOI: 10.1111/jgh.12831] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
19 Ma Y, Yuan Y, Ma X, Tang B, Hu X, Feng J, Tian L, Ji Y, Dou X. Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy. Exp Ther Med 2016;12:847-53. [PMID: 27446286 DOI: 10.3892/etm.2016.3365] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 He M, Wu Y, Wang M, Chen W, Yuan W, Jiang J. The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis. Evid Based Complement Alternat Med 2015;2015:971616. [PMID: 26508988 DOI: 10.1155/2015/971616] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Wu Y, Gan Y, Gao F, Zhao Z, Jin Y, Zhu Y, Sun Z, Wu H, Chen T, Wang J. Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma. PLoS One. 2014;9:e94864. [PMID: 24788140 DOI: 10.1371/journal.pone.0094864] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
22 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Sayyed DR, Nimse SB, Song KS, Sung N, Kim T. Multiplex SNP detection in multiple codons for accurate drug therapy. Chem Commun (Camb) 2014;50:14585-8. [PMID: 25307892 DOI: 10.1039/c4cc06625a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]